Clinical Feature |
Score |
Female gender |
+2 |
ALP:AST ratio |
|
<1.5 |
+2 |
1.5-3.0 |
0 |
>3.0 |
-2 |
Serum globulin or IgG above normal |
|
>2.0 |
+3 |
1.5-2.0 |
+2 |
1.0-1.5 |
+1 |
<1.0 |
0 |
ANA, SMA, or LKM-1 |
|
>1:80 |
+3 |
1:80 |
+2 |
1:40 |
+1 |
<1:40 |
0 |
AMA |
|
positive |
-4 |
Hepatitis viral markers |
|
Positive |
-3 |
Negative |
+3 |
Drug history |
|
Positive |
-4 |
Negative |
+1 |
Average alcohol intake |
|
<25 g/day |
+2 |
>60 g/day |
-2 |
Liver histology |
|
Interface hepatitis |
+3 |
Predominante lymphoplasmacytic infiltrate |
+1 |
Rosetting of liver cells |
+1 |
None of the above |
-5 |
Biliary changes |
-3 |
Other changes |
-3 |
Other autoimmune disease |
+2 |
Optional additional parameters |
|
Seropositivity for other defined autoantibodies |
+2 |
HLA DR3 or DR4 |
+3 |
Response to therapy |
|
Complete |
+2 |
Relapse |
+3 |
Interpretation of aggregate scores: |
|
Pre-treatment |
|
Definite AIH |
>15 |
Probable AIH |
10-15 |
Post-treatment |
|
Definite AIH |
>17 |
Probable AIH |
12-17 |
ALP: Alkaline Phosphatase; AST: Aspartate Transaminase; IgG: Immunoglobulin
G; ANA: Anti-nuclear Antibodies; SMA: Smooth Muscle Antibodies; LKM-1: Type
1 Liver-kidney Microsomal antibodies; AMA: Anti-Mitochondrial Antibodies; HLA:
Human Leucocyte Antigen |